S33138 (N-4-2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide, a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1212-1226

  Millan, Mark J ^a,c   Loiseau, Florence ^a   Dekeyne, Anne ^a   Gobert, Alain ^a   Flik, Gunnar ^b   Cremers, Thomas I ^b   Rivet, Jean Michel ^a   Sicard, Dorothée ^a   Billiras, Rodolphe ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CHARLES RIVER LABORATORIES   (United States)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(N [4 [2 [8 CYANO 1,3A,4,9B TETRAHYDRO[1]BENZOPYRANOL[3,4 C]PYRROL 2(3H) YL) ETHYL]PHENYL ACETAMIDE); AMPHETAMINE; COCAINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; KETAMINE; MUSCARINIC RECEPTOR; OLANZAPINE; PHENCYCLIDINE; PROLACTIN; RISPERIDONE; S 33138; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENCY; FRONTAL CORTEX; HYPERACTIVITY; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

ACETANILIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOPYRANS; DOPAMINE ANTAGONISTS; MALE; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 40849116470     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.134536     Document Type: Article

References (81)

1. Abi-Dargham A and Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15-27.
2. Bacciottini L, Passani MB, Mannaioni PF, and Blandina P (2001) Interactions between histaminergic and cholinergic system in learning and memory. Behav Brain Res 124:183-194.
3. 3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur J Neurosci 21:3415-3426.
4. Beer JS and Ochsner KN (2006) Social cognition: a multi-level analysis. Brain Res 1079:98-105.
5. Ben-Jonathan N and Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763.
6. 3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology 180:705-715.
7. Chudasama Y and Robbins TW (2004) Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology 174:86-98.
8. Clements RL and Greenshaw AJ (2005) Differential effects of 7-OH-DPAT and apomorphine on hyperactivity induced by MK-801 (dizocilpine) in rats. Neuropharmacology 49:1007-1016.
9. Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan R, Decker MW, and Fox GB (2007) Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 73:1123-1134.
10. 1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 22:1-17.
11. Drago F, Contarino A, Marino R, Anzallo C, Valerio C, Rampello L, Raffaele R, and Scapagnini U (1997) Effects of acute or chronic administration of risperidone on motor and sexual behaviour of male rats. Pharmacol Res 35:17-25.
12. El-Ghundi M, O'Dowd BF, and George SR (2007) Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci 18:37-66.
13. Geyer MA and Ellenbroek B (2003) Animal behaviour models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079.
14. Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154.
15. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, and Velligan DI (2005) Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 25:60-69.
16. 1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20:1208-1215.
17. 3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171-174.
18. Hagan JJ and Jones DNC (2005) Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31:830-853.
19. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49:77-105.
20. Horner WE, Johnson DE, Schmidt AW, and Rollema H (2006) Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol, 558:96-97.
21. Hou Y, Wu CF, Yang JY, and Guo T (2006) Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog Neuropsychopharmacol Biol Psychiatry 30:1486-1495.
22. 2A receptor minimally contribute to clozapine induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42.
23. Ito C (2004) The role of the central histaminergic system on schizophrenia. Drug News Perspect 17:383-965.
24. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, and Rollema H (2005a) The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol 506:209-219.
25. 3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925.
26. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40.
27. Kapur S, Agid O, Mizrahi R, and Li M (2006) How antipsychotics work: from receptors to reality. NeuroRx 3:10-21.
28. 3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur J Neurosci 22:1741-1750.
29. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JW, Meltzer HY, Green MF, Miller del D, Canive JM, et al. (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033-2046.
30. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
31. 3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anticholinesterases. J Neurosci Methods 157:25-31.
32. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179:567-575.
33. Lee KH, Brown WH, Egleston PN, Green RDJ, Farrow TFD, Hunter MD, Parks RW, Wilkinson ID, Spence SA, and Woodruff PWR (2006) A functional magnetic resonance imaging study of social recognition in schizophrenia during an acute episode and after recovery. Am J Psychiatry 163:1926-1933.
34. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45:174-181.
35. Lewis DA and Gonzalez-Burgos G (2006) Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016-1022.
36. Li Z, Huang M, Ichikawa J, Dai J, and Meltzer HY (2005) N-Desmethylchozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30:1986-1995.
37. Lieberman JA (2005) Recent advances in the clinical use of atypical antipsychotics. CNS Spectr 10:4.
38. Manoach DS (2003) Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 660:285-298.
39. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenbeck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
40. 2A receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 297:357-363.
41. Meltzer HY (2004) Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9:15-24.
42. Meltzer HY, Li Z, Kaneda Y, and Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
43. 3 knock-out mice (KO) mice pre-treated with beta-amyloid peptide is affected by cannabinoid CB1 receptor antagonist. Eur Neuropsychopharmacol 16:S256.
44. Millan MJ (2005) NMDA receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30-53.
45. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J-M, Newman-Tancredi A, Audinot V, and Maurel S (1999) Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine (PCP) versus amphetamine: importance of nucleus accumbens-localized serotonin (5-HT)2A sites for induction of locomotion by PCP in the rat. Eur J Neurosci 11:4419-4432.
46. 3-receptors: II. Functional and behavioural profile compared with GR18,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073.
47. 2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100:954-967.
48. 2 receptor antagonist and potential antipsychotic agent: I. receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 324:587-599.
49. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373.
50. 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174:341-357.
51. 2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 324:600-611.
52. Mirza NR and Stolerman IP (2000) The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology 148:243-250.
53. Moore NA (1999) Behavioural pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 174:5-11.
54. 3 receptor. J Pharmacol Exp Ther 300:621-628.
55. 2A receptor blockade. J Pharmacol Exp Ther 288:590-596.
56. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology 15:53-61.
57. Ninan I and Kulkarni SK (1996) Clozapine-induced cognitive dysfunction in mice. Methods Find Exp Clin Pharmacol 18:367-372.
58. 2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats. Neurobiol Learning Memory 87:385-390.
59. Passetti F, Levita L, and Robbins TW (2003) Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav Brain Res 138:59-69.
60. 2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 32:273-283.
61. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19:4627-4633.
62. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
63. Rezvani AH, Caldwell DP, and Levin ED (2006) Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. Prog Neuropsychopharmacol Biol Psychiatry 30:190-197.
64. 3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 31:2368-2375.
65. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163:362-380.
66. Sarter M, Nelson CL, and Bruno JP (2005) Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 31:117-138.
67. 1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol 559:155-166.
68. Shirzadi AA, Ghaemi SN (2006) Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 14:152-164.
69. 3 receptors on learning and memory in the rat. Eur J Pharmacol 336:107-112.
70. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43.
71. Svensson TH (2003) α-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145-1158.
72. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, and Braff DL (2006) Startle gating deficits in a large cohort of patients with schizophrenia. Arch Gen Psychiatry 63:1325-1335.
73. Tanaka S (2006) Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Neuroscience 139:153-171.
74. Terry AV, Hill WD, Parlich V, Walker JL, Evans DR, and Mahadik SP (2003) Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 28:300-309.
75. Thornton AE, Van Snellenberg JX, Sepehry AA, and Honer WG (2006) The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 20:335-346.
76. Turrone P, Kapur S, Seeman MV, and Flint AJ (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133-135.
77. 2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68:363-370.
78. 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191-202.
79. Woodward ND, Purdon SE, Meltzer HY, and Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472.
80. 3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 31:1382-1392.
81. Zmarowski A, Sarter M, and Bruno JP (2007) Glutamate receptors in nucleus accumbens mediate regionally selective increases in cortical acetylcholine release. Synapse 61:115-123.